Grant: CIHR New Investigator
McGill University
$300,000.00
Uncovering the molecular pathways that drive resistance to targeted cancer therapies through functional genetics
EF 2012-13
Résumé
Clinical trials with targeted cancer therapeutics have demonstrated that the benefit of these agents is frequently limited to small groups of patients. Moreover, this benefit is often limited, due to the rapid development of resistance. Thus, we need biomarkers that can identify patients that will respond to the therapy and ways to anticipate common resistance mechanisms. Understanding resistance mechanisms will help to optimize treatment options to overcome drug resistance.
In this proposal, we will uncover the molecular pathways that confer resistance to targeted cancer therapies, using unbiased genetic tools that allow us to manipulate the expression of many different genes in cancer cells. We will focus on mechanisms of drug resistance to several tyrosine kinase inhibitors, which are currently used to treat many cancers including several subtypes of lung cancer. Candidate resistance genes will be investigated in a variety of model systems, including cell culture and mouse models of cancer, to identify the mechanism by which they drive resistance. The expression of these candidate biomarkers will be examined in tumour samples of cancer patients to determine whether they are predictive of clinical response. Finally, our study will also provide potential treatment strategies to overcome drug resistance and result in clinical benefit for cancer patients.
Programme
CIHR New Investigator
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
268796
Name
Huang Sidong
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
New Investigators A
Projecttitle
Uncovering the molecular pathways that drive resistance to targeted cancer therapies through functional genetics
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
CIHR New Investigator
Keyworddelim
Drug Resistance; Genetic Screens; Targeted Cancer Therapy
Abstract
Clinical trials with targeted cancer therapeutics have demonstrated that the benefit of these agents is frequently limited to small groups of patients. Moreover, this benefit is often limited, due to the rapid development of resistance. Thus, we need biomarkers that can identify patients that will respond to the therapy and ways to anticipate common resistance mechanisms. Understanding resistance mechanisms will help to optimize treatment options to overcome drug resistance.
In this proposal, we will uncover the molecular pathways that confer resistance to targeted cancer therapies, using unbiased genetic tools that allow us to manipulate the expression of many different genes in cancer cells. We will focus on mechanisms of drug resistance to several tyrosine kinase inhibitors, which are currently used to treat many cancers including several subtypes of lung cancer. Candidate resistance genes will be investigated in a variety of model systems, including cell culture and mouse models of cancer, to identify the mechanism by which they drive resistance. The expression of these candidate biomarkers will be examined in tumour samples of cancer patients to determine whether they are predictive of clinical response. Finally, our study will also provide potential treatment strategies to overcome drug resistance and result in clinical benefit for cancer patients.
Competitiondate
201209
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Huang, Sidong
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~